PO.MCB10.01 · 分子与细胞生物学

Non-invasive screening of gynecologic tumors using miRNAs in urinary extracellular vesicles

海报缩略图:Non-invasive screening of gynecologic tumors using miRNAs in urinary extracellular vesicles
编号 2066 展板 26 时间 4/20 09:00–12:00 区域 Section 25 主讲 Atsushi Satomura
分会场 MicroRNAs as Cancer Biomarkers, Therapeutic Targets, and Modulators of Treatment Response
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Hiroko Matsumiya1, Atsushi Satomura2, Hiroshi Asano1, Hiroyuki Yamazaki1, Ryutaro Yamamoto1, Keiichiroh Akabane1, Ryo Tamaki1, Hiroyuki Kurosu1, Kei Ihira1, Daisuke Endo1, Takashi Mitamura1, Yosuke Konno1, Takeshi Umazume1, Motoki Mikami3, Yuki Ichikawa3, Hidemichi Watari1

1Hokkaido University Graduate School of Medicine, Hokkaido, Japan,2Craif USA, San Diego, CA,3Craif, Tokyo, Japan

摘要 Abstract

Background: Gynecologic malignancies constitute the second leading cause of cancer-related morbidity and mortality among women worldwide, following breast cancer. Despite the availability of effective screening programs, participation remains limited in several regions because of psychological reluctance toward pelvic examinations (e.g., approximately 40% in Japan) and constrained clinical resources. To address this issue, we explored a non-invasive screening strategy based on comprehensive microRNA (miRNA) profiling of urinary extracellular vesicles (uEVs). Methods: This study enrolled both pregnant and non-pregnant women with gynecologic diseases, along with healthy counterparts. In total, 456 urine samples were collected, from which uEVs were isolated and subjected to comprehensive miRNA profiling. A subset comprising 121 disease cases (84 malignant and 37 benign tumors) and 121 age-matched healthy non-pregnant controls was used to establish a diagnostic model. The dataset was randomly divided into training (N = 90) and holdout (N = 31) sets for performance evaluation. The resulting model was subsequently applied to pregnant women with gynecologic diseases and healthy pregnant women to assess its generalizability and diagnostic performance. Results: Differential expression analysis in the training set between disease cases and healthy controls identified 25 miRNAs with significant expression changes. A diagnostic model constructed using these differentially expressed miRNAs achieved an AUC of 0.907, with sensitivity and specificity of 0.867 and 0.856, respectively. When applied to the holdout set, the model maintained high performance (AUC = 0.937; sensitivity = 0.889; specificity = 0.944). Both malignant and benign tumors were detected with high scores in non-pregnant women, irrespective of cancer type or disease stage. Although healthy pregnant women, who were not included in model training, showed low predicted cancer probabilities, pregnant women with gynecologic diseases exhibited slightly reduced scores compared with their non-pregnant counterparts. Conclusions: Our results suggest that urinary uEV-miRNA profiling combined with machine learning enables accurate screening of gynecologic diseases. This non-invasive approach may complement general health checkups and enhance gynecologic screening rates, thereby contributing to earlier diagnosis and improved outcomes.
利益披露 Disclosure
H. Matsumiya, None. A. Satomura, Craif USA Inc. Employment, Stock Option. H. Asano, None.. H. Yamazaki, None.. R. Yamamoto, None.. K. Akabane, None.. R. Tamaki, None.. H. Kurosu, None.. K. Ihira, None.. D. Endo, None.. T. Mitamura, None.. Y. Konno, None.. T. Umazume, None. M. Mikami, Craif Inc. Employment, Stock Option. Y. Ichikawa, Craif Inc. g., Board of Directors, non-salaried role), Stock, Stock Option. H. Watari, None.

在会议检索中打开